Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2018
At a glance
- Drugs CYD TDV (Primary)
- Indications Dengue
- Focus Adverse reactions
- Sponsors sanofi pasteur
- 05 Feb 2018 Planned End Date changed from 2 Jan 2019 to 22 Oct 2018.
- 28 Jun 2017 Planned End Date changed from 1 Aug 2019 to 2 Jan 2019.
- 25 Oct 2016 Status changed from recruiting to active, no longer recruiting.